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ABSTRACT 29 
It is now well established that several cellular proteins that are components of promyelocytic 30 
leukaemia nuclear bodies (PML-NBs, also known as ND10) have restrictive effects on 31 
herpesvirus infections that are countered by viral proteins that are either present in the virion 32 
particle or are expressed during the earliest stages of infection. For example, herpes simplex 33 
virus 1 (HSV-1) immediate-early (IE) protein ICP0 overcomes the restrictive effects of PML-34 
NB components PML, Sp100, hDaxx and ATRX while human cytomegalovirus IE protein 35 
IE1 and tegument protein pp71 target PML and Sp100, and hDaxx and ATRX, respectively. 36 
The functions of these viral regulatory proteins are in part interchangeable, thus both IE1 and 37 
pp71 stimulate the replication of ICP0-null mutant HSV-1, while ICP0 increases plaque 38 
formation by pp71-deficient HCMV. Here, we extend these studies by examining proteins 39 
that are expressed by Epstein-Barr virus (EBV). We report that EBV tegument protein 40 
BNRF1, discovered by others to target the hDaxx/ATRX complex, increases the replication 41 
of both ICP0-null mutant HSV-1 and pp71-deficient HCMV. In addition, EBV protein 42 
EBNA-LP, which targets Sp100, also augments ICP0-null mutant HSV-1 replication. The 43 
combination of these two EBV regulatory proteins had a greater effect than each one 44 
individually. These findings enhance the concept that disruption of the functions of PML-NB 45 
proteins is important for efficient herpesvirus infections. 46 
 47 
IMPORTANCE 48 
Whether a herpesvirus initiates a lytic infection in a host cell or establishes quiescence or 49 
latency is influenced by events that occur soon after the viral genome has entered the host cell 50 
nucleus. Certain cellular proteins respond in a restrictive manner to the invading pathogen 51 
DNA, while viral functions are expressed that counteract the cell mediated repression. One 52 
aspect of cellular restriction of herpesvirus infections is mediated by components of nuclear 53 
structures known as PML Nuclear Bodies (PML NBs) or ND10. Members of the alpha, beta 54 
and gamma herpesvirus families all express proteins that interact with, degrade or otherwise 55 
counteract the inhibitory effects of various PML NB components. Previous work has shown 56 
that there is the potential of functional interchange between these viral proteins expressed by 57 
alpha and beta herpesviruses, despite a lack of obvious sequence similarity. Here this concept 58 
is extended to include a member of the gamma herpesviruses. 59 
 60 
  61 
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INTRODUCTION 62 
Studies over the past two decades performed in several laboratories have established that 63 
there are many connections between the replication of different human herpesvirus members 64 
and cellular structures known as promyelocytic leukemia nuclear bodies (PML NBs, also 65 
known as ND10) (reviewed in (1-5)). The genomes of members of the alpha, beta and gamma 66 
herpesvirus families have all been observed in close association with the proteins that make 67 
up PML NBs (6-10), and these viruses typically express proteins that disrupt the functions of 68 
one or more PML NB components (see reviews cited above and references therein). As 69 
described in the above cited work, it has been established that one function of PML NBs is to 70 
limit the replication of many different classes of virus, and that the viral proteins that disturb 71 
PML NB functions overcome these restrictive effects.  72 
If such effects are of general importance in regulating the efficiency of certain viral 73 
infections, it is possible that the activities of a protein of one virus that targets PML NBs may 74 
be substituted by those of another viral protein with analogous functions, even if the viral 75 
proteins in question share little or no obvious sequence similarity. Over the past few years 76 
this hypothesis has been tested in a variety of scenarios. For example, it was found that the 77 
functions of herpes simplex virus 1 (HSV-1) immediate-early (IE) protein ICP0 could be at 78 
least partially replaced by members of the ICP0 family of proteins expressed by other alpha 79 
herpesviruses (11).  ICP0 induces the degradation or disrupts the functions of several PML 80 
NB components, for example PML, Sp100, hDaxx and ATRX (12-16), each of which has 81 
been shown to have a role in restricting herpesvirus infections. Human cytomegalovirus 82 
(HCMV) proteins IE1 (which targets PML and Sp100; (15, 17-20)) and pp71 (which interacts 83 
with and can induce the degradation of hDaxx, and disrupts the hDaxx/ATRX complex; (21-84 
26)) also improve the replication of ICP0-null mutant HSV-1, and the two HCMV proteins in 85 
combination were almost as effective as ICP0 itself in the cell type examined (22). 86 
Conversely, prior expression of ICP0, like IE1, stimulates wild type (wt) and pp71 mutant 87 
HCMV plaque formation, and IE gene expression of IE1 mutant HCMV (27). In some ways 88 
even more strikingly, the Gam1 protein of chicken adenovirus (which induces degradation of 89 
PML (28, 29)) also strongly stimulates ICP0 null mutant plaque formation and gene 90 
expression (29). Thus there are now many examples of at least partial functional replacement 91 
of one viral protein that affects PML NB activities by another. 92 
 In this report we describe experiments that test whether proteins expressed by 93 
Epstein-Barr virus (EBV), a member of the gamma herpesvirus family, can also improve 94 
replication of ICP0 null mutant HSV-1. We constructed cells that express the EBV tegument 95 
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protein BNRF1 (which disrupts the hDaxx/ATRX complex and is the functional albeit 96 
unrelated homologue of HCMV pp71; (5, 30, 31)) or protein EBNA-LP (which targets 97 
Sp100; (32, 33)) and also cells that express these EBV proteins in combination. We found 98 
that EBNA-LP and to a greater extent BNRF1 allowed improved ICP0 null mutant HSV-1 99 
plaque formation, while the combination of these two proteins had an even greater effect. 100 
Furthermore, we found that BNRF1 could improve gene expression during pp71 mutant 101 
HCMV infection almost as efficiently as pp71 itself. These observations further strengthen 102 
the concept of functional interchange between herpesviral proteins that have related effects 103 
on PML NBs or their components, even in the absence of apparent sequence similarity. 104 
 105 
MATERIALS AND METHODS 106 
Viruses and cells 107 
HSV-1 wild type (wt) strain 17+ was used, from which the ICP0 null mutant dl1403 was 108 
derived (34). Virus dl1403/CMVlacZ is a derivative of dl1403 that contains the lacZ gene 109 
under the control of the HCMV promoter/enhancer inserted into the tk gene was a gift from 110 
Chris Preston. The HCMV pp71 deletion mutant ADsubUL82 (35) was kindly provided by 111 
Tom Shenk, and was used in conjugation with the AD169 parental wt strain. HFT cells 112 
expressing ICP0 were used for the growth of stocks of ADsubUL82 (27). HepaRG cells (36) 113 
and a derivative expressing the tetracycline repressor linked to EGFP (HA-TetR cells) have 114 
been described previously (37), and were grown in William’s Medium E supplemented with 115 
10% fetal bovine serum Gold (PAA Laboratories Ltd), 2 mM glutamine, 5 µg/ml insulin and 116 
500 nM hydrocortisone. U2OS and HEK-293T cells, and human diploid fibroblasts 117 
immortalized by expression of human telomerase from a lentivirus vector (38) (HFT cells; 118 
lentivirus and cells kindly provided by David Davido and Chris Boutell, respectively) were 119 
grown in Dulbecco’s Modified Eagles’ Medium supplemented with 10% fetal calf serum 120 
(FCS). BHK cells were grown in Glasgow Modified Eagles’ Medium supplemented with 121 
10% new born calf serum and 10% tryptose phosphate broth. All cell growth media were 122 
supplemented with 100 units/ml penicillin and 0.1 mg/ml streptomycin. 123 
Plasmids and lentiviral vectors 124 
Lentivirus vector plasmids expressing the tetracycline repressor linked to a nuclear 125 
localization signal and enhanced green fluorescent protein (pLKOneo.EGFPnlsTetR) and IE1 126 
or myc-tagged pp71 from a tetracycline inducible promoter have been described previously 127 
(22, 37). Analogous vectors expressing FLAG tagged BNRF1 (with blasticidin resistance) 128 
and EBNA-LP (with either G418 or puromycin resistance) with a FLAG tag at its N-terminal 129 
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end (with 4 W repeats, derived from plasmid pSG5-LP (39), kindly provided by Paul Ling) 130 
were constructed. For single inducible expression of these proteins, the BNRF1 vector and 131 
the puromycin resistance version of the EBNA-LP could be used to transduce HA-TetR cells. 132 
Some experiments utilized human fibroblast derived HFT-TetR cells (27) which were 133 
transduced with the blasticidin resistant BNRF1 vector. For expression of EBNA-LP in HFT 134 
derived cells, sequential transductions were performed with a polycistronic vector expressing 135 
puromycin resistance and the tetracycline repressor (and also EYFP in an inducible manner; 136 
kindly provided by Chris Boutell) with the G418 resistant version of the EBNA-LP cells. 137 
These cells could then be further transduced with the BNRF1 vector, thus creating HFT 138 
derived cells that express both BNRF1 and EBNA-LP in an inducible manner. Vectors that 139 
express myc tagged Zta, Rta or EBNA1 were also constructed for this study using PCR of the 140 
relevant open reading frames and insertion in place of the ICP0 open reading frame in 141 
plasmid pLDT-cICP0 (37). The EBNA1 sequence is a version lacking most of the gly-ala 142 
repeat (40). 143 
Lentivirus transductions and induction of protein expression 144 
Lentivirus transduction, selection of transduced cells and maintenance of cell lines were as 145 
described previously (41). Selection during routine culture used puromycin at 500 ng/ml, 146 
G418 at 0.5 mg/ml or blasticidin (Invitrogen) at 1 μg/ml, or combinations thereof, as 147 
relevant. The antibiotics were omitted from cells seeded for and during experimentation. For 148 
induction of protein expression, cells were treated with medium containing doxycycline (BD 149 
Biosciences) at 100 ng/ml for various times as indicated in the text, and throughout the 150 
duration of an experiment. 151 
Virus plaque assays 152 
For determination of relative plaque forming efficiencies of ICP0 null mutant HSV-1, cells 153 
were seeded for plaque assays into 24-well dishes at 1 x 105 cells per well, then infected the 154 
following day with appropriate sequential 3-fold dilutions of dl1403/CMVlacZ. After virus 155 
adsorption, the cells were overlayed with medium containing 1% human serum, then plaques 156 
were detected by staining for β-galactosidase expression in cells within the plaques 24 h later 157 
(42). Relative efficiencies of plaque formation were calculated by comparing the number of 158 
virus plaques in each cell line in wells infected with the same dilution of virus. Ratios over a 159 
number of dilutions were calculated and averaged, and the results presented were derived 160 
from at least two dilutions from at least 2 independent experiments. This method gives a 161 
more realistic comparison of plaque formation efficiencies than headline apparent titres 162 
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because the plaque formation efficiency of ICP0 null mutant HSV-1 varies in a non-linear 163 
manner with respect to dilution. 164 
 For assay of HCMV plaque formation, HFT based cells were seeded into 24-well 165 
dishes, treated or not with doxycycline the following day, then infected with the relevant 166 
HCMV virus at appropriate multiplicities. At 3 hours after virus adsorption, the virus 167 
inoculum was removed and replaced with fresh medium. Plaques were stained at 10 days 168 
after infection by immunological detection of UL44, which is abundantly expressed in the 169 
cells that constitute a plaque. Cell monolayers were fixed with formaldehyde and treated with 170 
NP40 as for immunofluorescence staining, washed twice with phosphate-buffered saline 171 
(PBS) containing 0.1% Tween-20 (PBST), then treated with PBST containing 5% dried milk 172 
for 30 minutes before being incubated for 2 h at room temperature with anti-UL44 173 
monoclonal antibody. Following washing three times with PBST and incubation with horse 174 
radish peroxidase conjugated goat anti-mouse secondary antibody for 1 h, the monolayers 175 
were washed with PBST three times and plaques were revealed by incubation with 0.2 ml 176 
True Blue solution (Insight Biotechnology, Product Code 50-7802) for 10 minutes. 177 
Western blot analysis. 178 
Cells were seeded into 24-well dishes at 1 x 105 cells per well. After the relevant 179 
experimental manipulations, the cells were washed twice with PBS before harvesting in SDS-180 
PAGE loading buffer. Proteins were resolved on 7.5% SDS-gels, then transferred to 181 
nitrocellulose membranes by western blotting. The following antibodies were used: anti-182 
IE1/2 mouse monoclonal antibody (mAb) E13 (Serotec), anti-IE1 mAb 1B12 (a gift from 183 
Tom Shenk) anti-myc tag mAb 9E10 (Santa Cruz), anti-tubulin mAb T4026 (Sigma-Aldrich), 184 
anti-FLAG tag mAb M2, anti-UL44 mAb ab6501 (Abcam) or mAb 10D8 (Santa Cruz), anti-185 
pp28 mAb ab6502 (Abcam), anti-pp71 mAb 2H10-9 (a gift from Tom Shenk) and anti-Sp100 186 
rabbit polyclonal antibody (rAb) SpGH (43). Antibodies to actin and HSV-1 proteins ICP4 187 
(mAb 58S), UL42 (mAb Z1F11) and VP5 (mAb DM165) were used as described previously 188 
(44). 189 
Immunoprecipitation 190 
Cells were seeded into 90 mm plates at 4.5 x 106 cells per plate, then treated as relevant with 191 
doxycyline for 24 h to induce protein expression. The cells were washed twice with 192 
phosphate buffered saline on ice, then 1.5 ml of lysis buffer (Pierce product number 87787, 193 
supplemented with complete protease inhibitor cocktail, Roche Diagnostics) was added 194 
directly onto the cells on the plate. After incubation on ice for 30 min, the plate was scraped 195 
with a syringe plunger and the harvested lysates were centrifuged at 13,000 rpm for 30 min at 196 
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4°C. The supernatant was pre-cleared by incubation with Protein G agarose beads (Millipore, 197 
16-201) for 30 min at 4°C, mixing end over end, then the beads were removed by 198 
centrifugation at 13,000 rpm for 10 min. Aliquots of the clarified supernatant (0.5 ml) were 199 
incubated at 4°C overnight, with end-over end- mixing, with 1 μg antibodies as follows: non-200 
specific pre-immune rabbit IgG, anti-ATRX rabbit polyclonal antibody (rAb) H-300 (Sigma), 201 
or anti-hDaxx rAb 07-471 (Upstate). Mixtures were then incubated with 30 μl fresh Protein G 202 
agarose beads for 60 min at 4°C with continuous mixing. The beads were washed four times 203 
with a buffer containing 10 mM Tris pH 7.6, 1.5 mM MgCl2, 300 mM NaCl, 5% glycerol, 0.2 204 
mM EDTA, 0.1% NP40, and protease inhibitors, then the beads were pelleted and 205 
resuspended in 30 μl gel loading mix. Proteins were separated using 6.75% SDS-206 
polyacrylamide Tris-glycine gels. After electroblotting overnight (50 mA, at 4°C), ATRX 207 
was detected using mAb 39F (a gift from Richard Gibbons) and hDaxx by mAb Daxx-208 
01(Santa Cruz Biotechnology).  209 
Immunofluorescence and confocal microscopy 210 
Cells on 13 mm diameter glass coverslips were fixed and prepared for immunofluorescence 211 
as described (45). PML was detected using mAb 5E10 (46), Sp100 with rAb SpGH, hDaxx 212 
with rAb 07-471 and ATRX with rAb H-300. Antibodies against the FLAG tag (mAb M2) 213 
and the myc tag (mAb 9E10) were also used. The secondary antibodies used were Alexa 555 214 
conjugated goat anti-mouse IgG and Alexa 633 conjugated goat anti-rabbit IgG (Invitrogen). 215 
The samples were examined using a Zeiss LSM 710 confocal microscope, with 488 nm, 561 216 
nm and 633 nm laser lines, scanning each channel separately under image capture conditions 217 
that eliminated channel overlap. The images were exported as tif files, minimally adjusted 218 
using Photoshop, then assembled into figures using Illustrator. 219 
 220 
RESULTS 221 
Inducible expression of BNRF1 222 
Recent work has shown that BNRF1, a member of the ORF75c family of proteins that are 223 
represented in the teguments of many gamma herpesviruses (5), is required for efficient EBV 224 
infection through a mechanism involving interaction with hDaxx and disruption of the 225 
hDaxx/ATRX complex (30, 31). As these properties are analogous to the pp71 tegument 226 
protein of HCMV, which is however unrelated by sequence, and because pp71 can stimulate 227 
ICP0-null mutant HSV-1 plaque formation (22) we set out to investigate whether BNRF1 228 
could also perform this function. A FLAG tagged BNRF1 open reading frame was inserted in 229 
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place of the ICP0 open reading frame of tetracycline inducible lentiviral vector pLDT-cICP0 230 
(37) then HA-TetR cells (37) were transduced to isolate a HepaRG cell line allowing 231 
inducible expression of BNRF1.  Analysis of these cells showed very abundant expression of 232 
BNRF1 following doxycycline treatment, with some expression detectable even before 233 
induction (Fig. 1A). Confirming previous data (31), we found that BNRF1 displaces hDaxx 234 
and ATRX from PML NBs without affecting PML or Sp100 (Fig. 1B) and disrupts the 235 
hDaxx/ATRX complex (Fig. 1C). We found that ICP0 null mutant HSV-1 had a pronounced 236 
increase in plaque formation in BNRF1 expression cells, both before induction (presumably 237 
due to the leaky basal expression) and particularly after induction (Fig. 1D). Quantification of 238 
these increases gave about 10- and 20-fold effects respectively, while BNRF1 expression had 239 
no effect on wt HSV-1 plaque formation efficiency (Fig. 1E). These increases were reflected 240 
in a general increase in IE, Early and Late viral gene expression during ICP0-null mutant 241 
HSV-1 infection of BNRF1 expressing cells (Fig. 1F). These data are analogous to those 242 
previously observed in cells expressing HCMV tegument protein pp71 (22). As part of this 243 
study, we also studied the effects of the expression of EBV proteins Zta and Rta on ICP0-null 244 
mutant HSV-1 plaque formation. Despite successful expression of both proteins using 245 
analogous methods, we found no evidence that either protein affected ICP0-null mutant 246 
infection (Fig. 2).   247 
EBNA-LP targets Sp100 and augments ICP0-null mutant HSV-1 plaque formation 248 
The theme of these and other recent studies is that herpesviral proteins that target PML-NB 249 
components may be partly interchangeable between different viruses. Another EBV protein 250 
that has been found to affect PML-NBs is EBNA-LP, which disperses Sp100 from these 251 
structures (32, 33). Therefore we constructed HA-TetR cells expressing FLAG-tagged 252 
EBNA-LP in an inducible manner. After induction, a variety of forms of EBNA-LP were 253 
expressed, with the slowest migrating major band having the expected mobility (Fig. 3A). 254 
Analysis of endogenous Sp100 in these cells showed that the sumoylated forms of the protein 255 
were greatly under-represented compared to the parental cells (Fig. 3A, lower panel). This 256 
was also evident in the uninduced cells, likely because of significant leaky expression of 257 
EBNA-LP prior to induction (Figs. 3B and 3C), albeit at levels insufficient for detection on 258 
western blots (Fig. 1A). The effect of EBNA-LP on the modified forms of Sp100 was not 259 
noted in the previous study (33), probably because the methods used here enable abundant 260 
expression of EBNA-LP in a very high proportion of the cells, and also because of the 261 
effectiveness of the Sp100 antibody utilized. Induction of EBNA-LP expression caused 262 
widespread loss of punctate Sp100 staining (consistent with the previous data; (33)), and this 263 
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also occurred in cells expressing EBNA-LP before induction (Fig. 3B). EBNA-LP had no 264 
apparent effect on the distribution of PML, however (Fig. 3C). ICP0-null mutant HSV-1 265 
plaque formation increased by around 10- to 25-fold in uninduced and induced cells 266 
respectively (Fig. 3D), without having any effect on wt HSV-1 (Fig. 3E). These results are 267 
consistent with a previous study that found that shRNA-mediated depletion of Sp100 268 
enhanced ICP0 null mutant HSV-1 plaque formation (41).  269 
Analysis of human fibroblasts expressing selected EBV regulatory proteins 270 
In order to extent these analyses, we also constructed immortalized human fibroblasts (HFT 271 
cells) expressing EBNA1, BNRF1 or EBNA-LP. Western blot analyses of examples of cells 272 
of this type are shown in Figs. 4A and 4B (in this case showing only two of the forms of 273 
EBNA-LP being expressed). Immunofluorescence analysis of such cells gave results that 274 
were consistent with those in the HepRG based cells described above, although in the HFT 275 
cells EBNA-LP expression was detectable in only about 50% of cells. Both EBNA-LP and 276 
BNRF1 increased ICP0 null mutant plaque formation in these HFT cells, but EBNA1 had 277 
little effect (Fig. 4C). We have previously found that when HCMV proteins IE1 and pp71 are 278 
expressed in combination, they are able to increase ICP0 null mutant HSV-1 plaque 279 
formation to a much greater extent than either used alone in both HepaRG and HFT cells (22, 280 
27). In an analogous manner, we found that the combination of EBNA-LP and BNRF1 was 281 
considerably more effective than either alone (Figs. 4A and 4C; see Materials and Methods 282 
for details of the construction of these cells).  283 
 We had previously found that prior expression of IE1 or the combination of IE1 and 284 
pp71 in HFT cells increased ICP0 null mutant plaque formation efficiency by about 14- and 285 
several hundred-fold respectively, while pp71 by itself had a 9-fold effect (27). As a further 286 
test of the functional analogy between BNRF1 and pp71, we analyzed the effect of the 287 
combination of BNRF1 with IE1 in comparison with cells expressing IE1 and pp71 (Fig. 4D). 288 
Again both combinations increased ICP0 null mutant plaque formation efficiency by several 289 
hundred fold (Fig. 4E), which is a far greater extent than IE1 alone (27) but still less than the 290 
greater than 2000-fold increase obtained by prior expression of ICP0 (27). 291 
Inhibition of recruitment of PML NB proteins to HSV-1 genomes by EBV proteins 292 
A hallmark of PML NB proteins is their response in the early stages of infection that leads to 293 
their recruitment to sites that are closely related to HSV-1 genomes (14, 45, 47). ICP0 294 
inhibits this recruitment response, while IE1 and pp71 inhibit that of PML/Sp100 and 295 
hDaxx/ATRX respectively, with these activities correlating with their stimulation of ICP0-296 
null mutant HSV-1 infection (22, 27). We found that this principle extended to the EBV 297 
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proteins under study, in that BNRF1 inhibited recruitment of hDaxx and ATRX without 298 
affecting that of Sp100 (Fig. 5). In cells expressing abundant EBNA-LP in which the Sp100 299 
signal was much reduced, the recruitment of Sp100 to ICP0 null mutant HSV-1 genomes was 300 
also greatly diminished (Fig. 5) although recruitment was still observed when Sp100 foci 301 
remained. Recruitment of PML and hDaxx appeared unaffected by expression of EBNA-LP 302 
(Fig. 5). These results are again consistent with the idea of some functional conservation, 303 
even in the absence of sequence similarity, of herpesvirus proteins that target PML-NBs or 304 
their constituents. They are also consistent with the hypothesis that inhibition of recruitment 305 
correlates with relief from the repression mediated by this group of proteins. 306 
BNRF1 complements pp71 mutant HCMV 307 
Given the functional analogies between BNRF1 and pp71, it was obviously of interest to 308 
determine whether BNRF1 could complement pp71-deficient HCMV. To this end, we 309 
utilized the HFT derived cells that express BNRF1 in a similar inducible manner (see Fig. 4) 310 
in comparison with cells that express pp71 using the same methodology (22). Infection of 311 
control HFT derived cells with the pp71-null mutant HCMV strain ADsubUL82 illustrated 312 
that, as expected, very little HCMV gene expression was detectable while in induced BNRF1 313 
cells viral IE, Early and Late proteins were abundantly detected (Fig. 6A). Infection of pp71 314 
and BNRF1 expressing cells in parallel with ADsubUL82 indicated that BNRF1 stimulated 315 
expression of IE1 to a similar extent as pp71 under these conditions, and while expression of 316 
IE2, UL44 and pp28 was not as efficient in BNRF1 compared to pp71 cells, these proteins 317 
were still readily detectable (Fig. 6B). Furthermore, we found that expression of BNRF1 318 
stimulated pp71-null mutant HCMV plaque formation to a degree similar to that of pp71 319 
itself (Fig. 6C). These results conform to the expectation that BNRF1 is the functional 320 
orthologue of pp71, and are reminiscent of previous observations indicating functional 321 
interchange between viral proteins that disrupt the hDaxx/ATRX complex (48, 49). 322 
 323 
DISCUSSION 324 
The results presented here provide a further illustration that inducible expression cell lines 325 
constructed by the use of lentiviral vectors provide an effective approach to the study of viral 326 
protein function. We wished to extend previous analyses into functional interchange between 327 
alpha and beta herpesvirus proteins that affect PML NB components to the gamma 328 
herpesviruses, based on previous studies from other groups. The results with BNRF1 are 329 
perhaps unsurprising, given the many established functional analogies between it and pp71 of 330 
HCMV (5, 31), and the fact that pp71 stimulates ICP0 null mutant HSV-1 plaque formation 331 
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(22, 27). Here we extend the functional similarities between the two proteins by showing that 332 
BNRF1 not only augments ICP0 null mutant HSV-1 replication, but it also stimulates pp71 333 
deficient HCMV infection and gene expression with similar efficiency to pp71 itself.   334 
 The results with EBNA-LP are consistent with the previous studies on its effects on 335 
Sp100 and PML-NBs (32, 33) and on the increase in ICP0 null mutant plaque formation 336 
efficiency in Sp100 depleted cells (41). Here we find that when expressed at low levels, 337 
EBNA-LP co-localizes with PML in PML NBs, and we confirm that high levels of EBNA-338 
LP disperse Sp100 from PML NBs, an effect that is probably connected with the loss of its 339 
sumoylated forms (Fig. 3A). On the basis that high level expression on Sp100 led to 340 
activation of the EBNA2 promoter, it was previously concluded that the role of EBNA-LP 341 
was to release Sp100 from PML NBs so it could act as a co-activator in concert with EBNA-342 
LP (33). With the advent of RNAi mediated depletion methodologies, it became apparent that 343 
Sp100 acts as a repressor rather than an activator in several herpesvirus infections (18, 41, 50, 344 
51), and the activation seen in earlier studies may be explained by dominant negative effects 345 
due to over-expression.  346 
We have previously suggested that intrinsic resistance conferred by PML NBs has a 347 
modular aspect, such that the repressive effects of PML, Sp100 and hDaxx/ATRX are 348 
additive (52). Thus while ICP0 overcomes the effects of all of these proteins, HCMV IE1 and 349 
pp71 target PML/Sp100 or hDaxx/ATRX respectively, and the combination of the two 350 
HCMV proteins has almost as great an effect of ICP0 itself in HepaRG-based cells (22). We 351 
found further evidence that is consistent with this hypothesis during the current studies, in 352 
that the combination of IE1 and BNRF1 stimulated ICP0 null mutant plaque formation to a 353 
similar extent as the IE1/pp71 combination (Fig. 4D). It is interesting to consider that, 354 
throughout our series of studies on RNAi mediated depletion of single or multiple PML NB 355 
components, or expression of heterologous viral regulatory proteins, we have never been able 356 
to create cells which, like U2OS cells, completely fail to restrict ICP0 null mutant HSV-1. 357 
Accordingly, we have been careful never to state that PML NBs are the sole regulatory 358 
mechanism involved, indeed it is known that other proteins and pathways also contribute to 359 
restriction. We would not expect any individual shRNA to substitute completely for ICP0, 360 
not only for the above reasons but also because remaining trace expression cannot be 361 
excluded, too low perhaps to be detected, but nonetheless sufficient to retain some biological 362 
activity. Expression of heterologous proteins tends to have more marked effects that single 363 
shRNAs, maybe because they achieve a greater inactivation of the restriction factor in 364 
question, but nonetheless they differ from ICP0 in that the latter seems uniquely capable of 365 
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inactivating all the factors involved in restriction as a whole. Thus a picture emerges of the 366 
full effect of restriction being made up of several separable components, and that sequential 367 
inactivation of two or more such components leads to greater levels of relief from restriction. 368 
The most effective combinations found so far are IE1/pp71 (or IE1/BNRF1), which would be 369 
expected to inactivate PML, Sp100, hDaxx and ATRX, with the result of restoration of ICP0 370 
null mutant plaque formation efficiency to within 2-fold of wt (in HepaRG cells), or about 4-371 
fold in HF-based cells. Given the normal defect of several hundred to a few thousand-fold, 372 
these degrees of complementation are very substantial.  373 
Finally, the results reported here are consistent with the hypothesis that viral 374 
activators can be grouped into two broad types, those that function through virus-specific 375 
mechanisms (such as specific sequences in the viral genome), and those that impede cell 376 
mediated restriction. Members of the former type would be expected to have virus-specific 377 
activities, while those of the latter may be in part functionally interchangeable between 378 
different viruses. 379 
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 395 
FIGURE LEGENDS  396 
Figure 1 397 
BNRF1 increases the replication efficiency of ICP0 null mutant HSV-1.  A. Inducible 398 
expression of BNRF1 in HepaRG-based cells after treatment with 100 ng/ml doxycycline 399 
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(Dox) for 24 h. B. Induction of BNRF1 expression causes the dispersal of hDaxx and ATRX, 400 
but not Sp100, from PML NBs. Each row of 3 images shows the separated and merged 401 
channels for the relevant proteins, as indicated. The top two rows show control HA-TetR 402 
cells, the lower pair show induced BNRF1 expressing cells. C. Induction of BNRF1 403 
expression causes the disruption of the hDaxx/ATRX complex. Extracts made from 404 
uninduced and induced control and BNRF1 expressing cells were used for 405 
immunoprecipitation with control, hDaxx or ATRX antibodies, as marked. Substantial co-406 
immuneprecipitation of hDaxx and ATRX occurred in the control extracts, but in BNRF1 407 
expressing cells this was reduced to antibody control levels. D. Expression of BNRF1 408 
increases ICP0 null mutant plaque formation. Virus dl1403/CMVlacZ was used to infect 409 
uninduced and induced control and BNRF1 cells at increasing 3-fold dilutions. Plaques were 410 
visualized by staining for the β-galactosidase marker gene at 24 h after infection. E. 411 
Quantification of plaque formation efficiencies from replicate experiments of the type shown 412 
in D. Relative plaque forming efficiency was calculated by comparing the number of plaques 413 
in the stated condition with the same input virus dilution. The upper panel shows the results 414 
with ICP0 null mutant HSV-1, the lower panel those using the corresponding wt virus 415 
control. F. Expression of BNRF1 increases the efficiency of viral gene expression in ICP0 416 
null mutant HSV-1 infections. Induced control and BNRF1 cells were infected at MOI 2 then 417 
samples taken at the indicated times after infection were analyzed for ICP4, VP5 and UL42 418 
expression. 419 
 420 
Figure 2 421 
Expression of EBV proteins Zta and Rta has no effect on the efficiency of ICP0 null mutant 422 
HSV-1 infection. A. HepaRG-based cells constructed to express FLAG-tagged Zta or myc-423 
tagged Rta were analyzed by immunofluorescence before (upper set of 6 images) or after 424 
(lower set of 6 images) induction with doxycycline. Pairs of images in vertical alignment 425 
show the EGFPnlsTetR fusion protein and the relevant epitope tag signals from the same 426 
field of cells. The controls are HA-TetR parental cells. B. The same cells were analyzed by 427 
western blotting for expression of FLAG-tagged Zta and myc-tagged Rta before and after 428 
induction. C. ICP0-null mutant plaque formation was analyzed in induced control, Zta and 429 
Rta expressing cells.  430 
 431 
 432 
 433 
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Figure 3 434 
EBNA-LP increases the replication efficiency of ICP0 null mutant HSV-1.  A. Inducible 435 
expression of EBNA-LP in HepaRG-based cells after treatment with 100 ng/ml doxycycline 436 
(Dox) for 24 h. Analysis of Sp100 indicated substantial loss of the sumoylated forms of this 437 
protein in the BNRF1 expressing cells. B. Induction of EBNA-LP expression causes the loss 438 
of Sp100 from PML NBs. Control and uninduced and induced HFT-EBNA-LP cells were 439 
stained for Sp100 and EBNA-LP as indicated. EGFP detects the nuclear localization of the 440 
EGFPnlsTetR fusion protein in these cells. A proportion of uninduced cells, particularly those 441 
expressing a low level of the TetR repressor, have detectable EBNA-LP expression and in 442 
these cells Sp100 staining is much reduced. This phenotype is widespread in induced cells. C. 443 
Cells as in panel B were stained for PML and EBNA-LP. PML staining was unaffected by 444 
expression of EBNA-LP, whose punctate foci largely co-localized with PML in uninduced 445 
cells, to a lesser extent in induced cells. D. Induction of EBNA-LP expression increases ICP0 446 
null mutant plaque formation. Virus dl1403/CMVlacZ was used to infect uninduced control 447 
and EBNA-LP cells at increasing 3-fold dilutions, then relative plaque forming efficiencies 448 
were calculated by comparing the numbers of plaques in the two cell types with the same 449 
input virus dilutions. E. EBNA-LP expression has no effect on the plaque formation 450 
efficiency of wt HSV-1. 451 
 452 
Figure 4 453 
The effects of expression of BNRF1, EBNA-LP and EBNA1 on ICP0 null mutant HSV-1 454 
gene expression in HFT cells. A. Western blot analysis of induced expression of EBNA-LP 455 
or BNRF1 or the combination of both in HFT-based cells. B. Inducible expression of EBNA1 456 
in HFT-derived cells, which were used for the control. C. The efficiency of ICP0 null mutant 457 
HSV-1 plaque formation was analyzed in cells analogous to the above after treatment with 458 
doxycycline, using the approach described in Figs 1 - 3. The results are expressed as fold 459 
increases above the level in control HFT cells. D. Western blot analysis of cells constructed 460 
to express combinations of HCMV proteins IE1 and pp71, or IE1 with BNRF1. E. Plaque 461 
formation analysis on ICP0 null mutant HSV-1 in HFT-based cells expressing combinations 462 
of IE1 and pp71, or IE1 and BNRF1, in comparison with control HFT cells.   463 
 464 
Figure 5 465 
Effect of expression of BNRF1 and EBNA-LP on recruitment of PML NB proteins to sites 466 
associated with HSV-1 genomes. Control cells or cells induced to express BNRF1 (HepaRG-467 
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based) or EBNA-LP (HF-based) were infected with ICP0 null mutant HSV-1 at low 468 
multiplicity then cells at the edges of developing plaques were analyzed for the localisation of 469 
ICP4, Sp100, hDaxx or ATRX as indicated. All the PML-NB proteins were relocated to sites 470 
associated with ICP4 (which strongly binds to HSV-1 DNA) in control cells (left-hand 471 
column, showing the indicated PML NB protein signal in a panel below that of ICP4 in each 472 
case). Recruitment of Sp100 but not hDaxx or ATRX occurs in BNRF1 expressing cells 473 
(central column), while recruitment of PML and hDaxx but not Sp100 occurs in cells 474 
expressing high levels of EBNA-LP (right-hand column).  475 
 476 
Figure 6 477 
BNRF1 increases viral gene expression during pp71 mutant HCMV infection. A. Control 478 
HFT cells expressing EYFP or FLAG-tagged BNRF1 were treated with doxycycline then 479 
infected with AD169sub82 (MOI 1). Samples were prepared over the following days and 480 
analyzed for expression of BNRF1 and HCMV proteins IE1, IE2, UL44 and pp28. B. BNRF1 481 
increases viral gene expression from pp71 mutant HCMV almost as efficiently as pp71. Cells 482 
induced to express myc-tagged pp71 or FLAG-tagged BNRF1 infected with AD169sub82 483 
(MOI 1) then samples were prepared over the following days and analyzed for expression of 484 
BNRF1 and HCMV proteins IE1, IE2, UL44 and pp28. C. Plaque formation analysis of 485 
pp71-null mutant HCMV strain AD169sub82 in cells induced to express pp71 or BNRF1. 486 
 487 
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Figure 1
BNRF1 increases the replication efficiency of ICP0 null mutant HSV-1.  A. Inducible expression of BNRF1 in HepaRG-based cells after 
treatment with 100 ng/ml doxycycline (Dox) for 24 h. B. Induction of BNRF1 expression causes the dispersal of hDaxx and ATRX, but not 
Sp100, from PML NBs. Each row of 3 images shows the separated and merged channels for the relevant proteins, as indicated. The top 
two rows show control HA-TetR cells, the lower pair show induced BNRF1 expressing cells. C. Induction of BNRF1 expression causes the 
disruption of the hDaxx/ATRX complex. Extracts made from uninduced and induced control and BNRF1 expressing cells were used for 
immunoprecipitation with control, hDaxx or ATRX antibodies, as marked. Substantial co-immuneprecipitation of hDaxx and ATRX occurred 
in the control extracts, but in BNRF1 expressing cells this was reduced to antibody control levels. D. Expression of BNRF1 increases ICP0 
null mutant plaque formation. Virus dl1403/CMVlacZ was used to infect uninduced and induced control and BNRF1 cells at increasing 3-fold 
dilutions. Plaques were visualized by staining for the β-galactosidase marker gene at 24 h after infection. E. Quantification of plaque formation 
efficiencies from replicate experiments of the type shown in D. Relative plaque forming efficiency was calculated by comparing the number 
of plaques in the stated condition with the same input virus dilution. The upper panel shows the results with ICP0 null mutant HSV-1, the 
lower panel those using the corresponding wt virus control. F. Expression of BNRF1 increases the efficiency of viral gene expression in ICP0 
null mutant HSV-1 infections. Induced control and BNRF1 cells were infected at MOI 2 then samples taken at the indicated times after infection 
were analyzed for ICP4, VP5 and UL42 expression.
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Figure 2
Expression of EBV proteins Zta and Rta has no effect on the efficiency of ICP0 null mutant HSV-1 infection. 
A. HepaRG-based cells constructed to express FLAG-tagged Zta or myc-tagged Rta were analyzed by immunofluorescence 
before (upper set of 6 images) or after (lower set of 6 images) induction with doxycycline. Pairs of images in vertical alignment 
show the EGFPnlsTetR fusion protein and the relevant epitope tag signals from the same field of cells. The controls are HA-TetR 
parental cells. B. The same cells were analyzed by western blotting for expression of FLAG-tagged Zta and myc-tagged Rta 
before and after induction. C. ICP0-null mutant plaque formation was analyzed in induced control, Zta and Rta expressing cells. 
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Figure 3
EBNA-LP increases the replication efficiency of ICP0 null mutant HSV-1.  A. Inducible expression of EBNA-LP in HepaRG-based cells 
after treatment with 100 ng/ml doxycycline (Dox) for 24 h. Analysis of Sp100 indicated substantial loss of the sumoylated forms of this 
protein in the BNRF1 expressing cells. B. Induction of EBNA-LP expression causes the loss of Sp100 from PML NBs. Control and 
uninduced and induced HFT-EBNA-LP cells were stained for Sp100 and EBNA-LP as indicated. EGFP detects the nuclear localization 
of the EGFPnlsTetR fusion protein in these cells. A proportion of uninduced cells, particularly those expressing a low level of the TetR 
repressor, have detectable EBNA-LP expression and in these cells Sp100 staining is much reduced. This phenotype is widespread in 
induced cells. C. Cells as in panel B were stained for PML and EBNA-LP. PML staining was unaffected by expression of EBNA-LP, whose 
punctate foci largely co-localized with PML in uninduced cells, to a lesser extent in induced cells. D. Induction of EBNA-LP expression 
increases ICP0 null mutant plaque formation. Virus dl1403/CMVlacZ was used to infect uninduced control and EBNA-LP cells at increasing 
3-fold dilutions, then relative plaque forming efficiencies were calculated by comparing the numbers of plaques in the two cell types with 
the same input virus dilutions. E. EBNA-LP expression has no effect on the plaque formation efficiency of wt HSV-1.
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Figure 4
The effects of expression of BNRF1, EBNA-LP and EBNA1 on ICP0 null mutant HSV-1 gene expression in HFT cells.
A. Western blot analysis of induced expression of EBNA-LP or BNRF1 or the combination of both in HFT-based cells. 
B. Inducible expression of EBNA1 in HFT-derived cells, which were used for the control. C. The efficiency of ICP0 null 
mutant HSV-1 plaque formation was analyzed in cells analogous to the above after treatment with doxycycline, using 
the approach described in Figs 1 - 3. The results are expressed as fold increases above the level in control HFT cells. 
D. Western blot analysis of cells constructed to express combinations of HCMV proteins IE1 and pp71, or IE1 with BNRF1. 
E. Plaque formation analysis on ICP0 null mutant HSV-1 in HFT-based cells expressing combinations of IE1 and pp71, or 
IE1 and BNRF1, in comparison with control HFT cells.  
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Figure 5
Effect of expression of BNRF1 and EBNA-LP on recruitment of PML NB proteins to sites associated with HSV-1 genomes. 
Control cells or cells induced to express BNRF1 (HepaRG-based) or EBNA-LP (HF-based) were infected with ICP0 null mutant 
HSV-1 at low multiplicity then cells at the edges of developing plaques were analyzed for the localisation of ICP4, Sp100, hDaxx 
or ATRX as indicated. All the PML-NB proteins were relocated to sites associated with ICP4 (which strongly binds to HSV-1 DNA) 
in control cells (left-hand column, showing the indicated PML NB protein signal in a panel below that of ICP4 in each case). 
Recruitment of Sp100 but not hDaxx or ATRX occurs in BNRF1 expressing cells (central column), while recruitment of PML and 
hDaxx but not Sp100 occurs in cells expressing high levels of EBNA-LP (right-hand column).
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Figure 6
BNRF1 increases viral gene expression during pp71 mutant HCMV infection. A. Control HFT cells expressing EYFP or 
FLAG-tagged BNRF1 were treated with doxycycline then infected with AD169sub82 (MOI 1). Samples were prepared over 
the following days and analyzed for expression of BNRF1 and HCMV proteins IE1, IE2, UL44 and pp28. B. BNRF1 increases 
viral gene expression from pp71 mutant HCMV almost as efficiently as pp71. Cells induced to express myc-tagged pp71 or 
FLAG-tagged BNRF1 infected with AD169sub82 (MOI 1) then samples were prepared over the following days and analyzed 
for expression of BNRF1 and HCMV proteins IE1, IE2, UL44 and pp28. C. Plaque formation analysis of pp71-null mutant 
HCMV strain AD169sub82 in cells induced to express pp71 or BNRF1.
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